Related Experiment Video
Updated: May 6, 2026
09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
21.1K
Alzheimer's disease: screening biomarkers using frequency doubling technology visual field
1Vision Care, 62 Forest Avenue, Quincy, MA 02169, USA.
ISRN Neurology
|November 5, 2013
Summary
Frequency Doubling Technology (FDT) visual field testing effectively identifies Alzheimer's disease (AD) biomarkers. This simple screening tool shows significant differences in patients with AD compared to controls, aiding early detection.
Area of Science:
- Ophthalmology
- Neurology
- Biomarker Discovery
Background:
- Alzheimer's disease (AD) poses a significant challenge for early diagnosis.
- Identifying reliable early biomarkers is crucial for timely intervention.
- Current diagnostic methods may not capture the earliest signs of neurodegeneration.
Purpose of the Study:
- To investigate the feasibility of Frequency Doubling Technology (FDT) visual field testing for identifying Alzheimer's disease (AD) biomarkers.
- To compare FDT results in AD patients with those in a control group without AD.
- To assess FDT's potential as an early screening tool for AD.
Main Methods:
- Participants diagnosed with AD and age-matched controls without AD underwent FDT visual field testing.
- FDT results were analyzed and compared against an age-normative database.
- The presence of AD biomarkers was evaluated based on screening criteria.
Main Results:
- FDT demonstrated a highly significant ability to identify visual system biomarkers in individuals with AD.
- A significant difference was observed between AD patients and the control group.
- The identified visual deficits were not attributable to any underlying ocular pathology.
Conclusions:
- Frequency Doubling Technology (FDT) visual field testing is a feasible and effective method for detecting early Alzheimer's disease biomarkers.
- FDT can serve as a valuable, non-invasive screening tool in a battery of tests for early AD detection.
- The visual system biomarker identified by FDT is specific to AD and independent of ocular conditions.
More Related Videos
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.4K
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
3.1K
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
01:23Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:30Dementia
696
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
696
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K